Why Grifols, S.A.’s (GRFS) Stock Is Down 5.61%
As of Friday, July 31, Grifols, S.A.’s GRFS share price has dipped by 5.61%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.
Commentary & Analysis
Is Grifols, S.A. (GRFS) Overvalued?
We dive into why Grifols, S.A. (GRFS) could be considered overvalued on 2026-07-30, based on AAII’s Value Score and Grade.Tudor Pop
Why Grifols, S.A.’s (GRFS) Stock Is Down 5.48%
As of Thursday, April 09, Grifols, S.A.’s GRFS share price has dipped by 5.48%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Grifols, S.A.’s (GRFS) Stock Is Down 6.71%
As of Tuesday, March 03, Grifols, S.A.’s GRFS share price has dipped by 6.71%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Grifols, S.A.’s (GRFS) Stock Is Up 5.66%
As of Wednesday, January 14, Grifols, S.A.’s GRFS share price has surged by 5.66%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | GRFS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $7,127.8 | $251.9 | 72% |
|
| Shares Out (Mil) | 777.5 | 50.8 | 92% |
|
| Institutional Ownership | 95.8% | 92.0% | 68% |
|
| Float (Mil) | 418.1 | 40.5 | 84% |
|
| Beta | 1.18 | 0.95 | 69% |
|
| Avg Daily Volume (000s) | 1,002 | 447 | 71% |
|
| Price Change (52-week) |
(21.9%) | 54.2% | 30% |
|
| Growth | GRFS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 6.2% | 14.0% | 42% |
|
| Net Income (5yr) | (9.0%) | (9.8%) | 30% |
|
| EPS (5yr) | (8.8%) | 16.3% | 22 |
|
| Dividends (5yr) | (14.9%) | 0.0% | 0% |
|
| Cash Flow (5yr) | 0.8% | (15.6%) | 65% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | GRFS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $8,478 | $39 | 82% |
|
| Net Income (TTM) (Mil) | $516 | ($43) | 79% |
|
| EPS (TTM) | $0.755 | ($1.600) | 58% |
|
| Operating Cash Flow (TTM) (Mil) | $1,246 | ($30) | 83% |
|
| Net Cash Flow (TTM) (Mil) | $145 | $3 | 82% |
|
| Long-Term Debt (Q1) (Mil) | $10,063 | $5 | 91% |
|
| Enterprise Value (Q1) (Mil) | $19,977 | $182 | 83% |
|
| Valuation | GRFS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.88 | 2.60 | 19% |
|
| P/E | 10.9 | 18.6 | 19% |
|
| Dividend Yield | 0.3% | 0.0% | 61% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | GRFS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 37.8% | 63.8% | 46% |
|
| Net Margin | 6.1% | (64.7%) | 52% |
|
| ROA | 2.2% | (49.7%) | 57% |
|
| ROE | 8.4% | (55.4%) | 53% |
|
| Liabilities to Assets | 60.3% | 30.3% | 54% |
|
| F-Score | 8 | 3 | 94% |
|
Grifols, S.A. did not pass any screens on 7/30/2026.
